Lord, Abbett & Co
CHRS icon

Lord, Abbett & Co’s Coherus Oncology CHRS Stock Holding History

Lord, Abbett & Co’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-143,360
Closed -$2.49M – 647
2020
Q4 		$2.49M Sell
143,360
-707,125
-83% -$12.6M 0.01% 625
2020
Q3 		$15.6M Buy
850,485
+33,717
+4% +$627K 0.05% 413
2020
Q2 		$14.6M Sell
816,768
-125,013
-13% -$2.12M 0.05% 418
2020
Q1 		$15.3M Sell
941,781
-2,130,459
-69% -$39.4M 0.07% 362
2019
Q4 		$55.3M Buy
3,072,240
+166,776
+6% +$3.08M 0.18% 164
2019
Q3 		$58.9M Buy
2,905,464
+491,126
+20% +$9.81M 0.2% 153
2019
Q2 		$53.4M Buy
+2,414,338
New +$41.9M 0.17% 205
2017
Q3 		– Sell
-225,592
Closed -$3.24M – 867
2017
Q2 		$3.24M Sell
225,592
-3,800
-2% -$73.1K 0.01% 823
2017
Q1 		$4.85M Sell
229,392
-33,162
-13% -$816K 0.01% 753
2016
Q4 		$7.39M Sell
262,554
-101,180
-28% -$2.83M 0.02% 645
2016
Q3 		$9.74M Buy
363,734
+95,161
+35% +$2.6M 0.03% 591
2016
Q2 		$4.54M Buy
268,573
+99,364
+59% +$1.87M 0.01% 732
2016
Q1 		$3.59M Sell
169,209
-13,320
-7% -$218K 0.01% 764
2015
Q4 		$4.19M Sell
182,529
-80,213
-31% -$2.06M 0.01% 769
2015
Q3 		$5.26M Sell
262,742
-107,203
-29% -$3.26M 0.02% 725
2015
Q2 		$10.7M Buy
+369,945
New +$9.35M 0.03% 628

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Lord, Abbett & Co's CHRS Position: Q1 2021 in Review

Lord, Abbett & Co sold out of Coherus Oncology (CHRS) in Q1 2021, closing a stake of 143,360 shares — an estimated $2.49M sold.

Lord, Abbett & Co first reported a position in CHRS in Q2 2015 and held it in 16 quarters. The position peaked at $58.9M in Q3 2019. 205 funds tracked by Wall St. Rank hold CHRS as of Q1 2021.

  • Lord, Abbett & Co reported no remaining Coherus Oncology position as of Q1 2021 after selling out during the quarter.
  • Lord, Abbett & Co sold 143,360 Coherus Oncology shares in Q1 2021, an estimated $2.49M.
  • Lord, Abbett & Co first reported a position in Coherus Oncology in Q2 2015 and held it in 16 quarters.
  • Lord, Abbett & Co's Coherus Oncology position peaked at $58.9M in Q3 2019.
  • 205 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2021.

Based on Lord, Abbett & Co's 13F filing for Q1 2021, filed 11 May 2021.